Amgen Inc. (NASDAQ:AMGN) Stock Has Average Price Target of $381.32 According to Brokerages

Shares of Amgen Inc. (NASDAQ:AMGN) have received a consensus rating of “Hold” from the thirty brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $383.46.

AMGN has been the subject of several recent analyst reports. Guggenheim boosted their price target on Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. UBS Group reaffirmed a “buy” rating and set a $430.00 price objective on shares of Amgen in a research report on Thursday, September 17th. Piper Sandler lifted their price objective on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Mizuho boosted their target price on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 6th.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Promising Sjögren’s disease trial results: Amgen reported statistically significant and clinically meaningful improvements in systemic Sjögren’s disease symptoms in the Phase 3 OASIZ 301 trial. Benefits remained evident through Week 48, with generally mild-to-moderate side effects. Dazodalibep could become a first-in-class treatment for a condition with no approved disease-modifying therapies, strengthening Amgen’s pipeline outlook. Amgen Is Up 7.9% After Positive Phase 3 Dazodalibep Data
• Positive Sentiment: Analyst support remains constructive: Scotiabank maintained its Buy rating on Amgen, which may reinforce confidence in the company’s valuation and growth prospects. Scotiabank Sticks to Its Buy Rating for Amgen
• Positive Sentiment: Dividend-growth appeal: Amgen was highlighted among dividend-growth stocks that could attract investors seeking income and growth as Treasury yields rise. This may broaden demand beyond biotech-focused investors. Dividend Growth Stocks Amid Rising Treasury Yields
• Neutral Sentiment: Investor attention increased: Amgen ranked among the most heavily searched stocks on Zacks, signaling heightened interest but not necessarily a change in fundamentals. Investors Heavily Search Amgen
• Neutral Sentiment: Jefferies reiterated its Hold rating, tempering the otherwise positive analyst backdrop. Reported zero short interest suggests limited short-covering influence, although the figure may reflect a data issue. Jefferies Sticks to Its Hold Rating

Amgen Price Performance

Shares of AMGN opened at $414.61 on Wednesday. The company has a market capitalization of $224.15 billion, a P/E ratio of 25.77, a price-to-earnings-growth ratio of 2.93 and a beta of 0.43. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a 50 day moving average of $406.13 and a 200 day moving average of $368.86. Amgen has a twelve month low of $269.77 and a twelve month high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the prior year, the firm posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts anticipate that Amgen will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Institutional Trading of Amgen

Large investors have recently modified their holdings of the company. State Street Corp boosted its position in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. Norges Bank purchased a new stake in shares of Amgen during the 4th quarter valued at about $2,164,162,000. Bank of America Corp DE purchased a new stake in shares of Amgen during the 2nd quarter valued at about $1,831,903,000. Capital World Investors lifted its stake in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.